All news

Solventum lifts 2026 EPS guidance after Q3 beat

StockStory · · AI-summarised by FinFlash

Solventum shares climbed about 5% in afternoon trading before settling at $91.19, up 4.6%, after the healthcare products maker reported third-quarter revenue of

So What?

The guidance lift supports the medtech spin-off's rerating, keeping shares near their 52-week high of $92.44; watch whether margin gains persist into 2027.

Read original source

SOLV company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.